Page last updated: 2024-11-07

prodan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

prodan: do not confuse with prodan in Chemline, RN 16893-85-9 which is disodium hexafluorosilicate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107729
CHEBI ID51909
SCHEMBL ID158933
MeSH IDM0115880

Synonyms (30)

Synonym
prodan
6-propionyl-2-(dimethylamino)naphthalene
NCGC00160619-01
1-[6-(dimethylamino)naphthalen-2-yl]propan-1-one
6-propionyl-2-dimethylaminonaphthalene
CHEBI:51909
2-propionyl-6-dimethylaminonaphthalene
70504-01-7
1-(6-(dimethylamino)-2-naphthalenyl)-1-propanone
1-propanone, 1-(6-(dimethylamino)-2-naphthalenyl)-
n,n-dimethyl-6-propionyl-2-naphthylamine, bioreagent, suitable for fluorescence, >=98.0% (hplc)
n,n-dimethyl-6-propionyl-2-naphthylamine
unii-3krl7r0zb7
3krl7r0zb7 ,
2-(dimethylamino)-6-propionylnaphthalene
1-[6-(dimethylamino)-2-naphthalenyl]-1-propanone
FT-0621309
1-(6-(dimethylamino)naphthalen-2-yl)propan-1-one
SCHEMBL158933
AKOS016846014
J-100113
mfcd00056615
n,n-dimethyl-6-propionyl-2-phthylamine
DS-11913
DTXSID60990711
Q27122985
D4678
C76247
VCA50401
SB80148

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Amorphous solid dispersions (ASDs) are a promising formulation strategy to increase both the apparent aqueous solubility and bioavailability of poorly water-soluble drugs."( Mechanistic understanding of the phase behavior of supersaturated solutions of poorly water-soluble drugs.
Hall, SD; Mohutsky, MA; Posada, MM; Taylor, LS; Tres, F, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
2-acyl-6-dimethylaminonaphthaleneA naphthalene with an acyl group at poition 2 and an amino function (either substituted or unsubstituted) at poition 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (103)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (4.85)18.7374
1990's22 (21.36)18.2507
2000's42 (40.78)29.6817
2010's32 (31.07)24.3611
2020's2 (1.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.93 (24.57)
Research Supply Index4.66 (2.92)
Research Growth Index5.07 (4.65)
Search Engine Demand Index103.05 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.95%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other104 (99.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]